LTR Pharma Limited
LTPLF
$0.27
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -33.43% | 66.88% | -- | -- | -- |
| Gross Profit | 73.49% | -22.52% | -- | -- | -- |
| SG&A Expenses | 139.08% | 216.25% | 405.20% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1,080.00% | 1,211.02% | 1,435.20% | -- | -- |
| Total Operating Expenses | 114.96% | 194.24% | 374.27% | -- | -- |
| Operating Income | -100.21% | -182.78% | -370.92% | -- | -- |
| Income Before Tax | -100.33% | -181.89% | -365.76% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -100.33% | -181.89% | -365.76% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -100.33% | -181.89% | -365.76% | -- | -- |
| EBIT | -100.21% | -182.78% | -370.92% | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -134.59% | -247.83% | -541.18% | -- | -- |
| Normalized Basic EPS | -137.80% | -250.88% | -537.50% | -- | -- |
| EPS Diluted | -134.59% | -247.83% | -541.18% | -- | -- |
| Normalized Diluted EPS | -137.80% | -250.88% | -537.50% | -- | -- |
| Average Basic Shares Outstanding | -47.24% | -46.81% | -46.36% | -- | -- |
| Average Diluted Shares Outstanding | -47.24% | -46.81% | -46.36% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |